2025 annual financial data

Recursion Pharmaceuticals 2025 Net margin

Direct answer

Net margin was -863.35%.

Operating income was -648,132,000 USD and net income was -644,759,000 USD.
Operating cash flow was -371,808,000 USD.

Get free Recursion Pharmaceuticals email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
74,681,000 USD
Operating income
-648,132,000 USD
Net income
-644,759,000 USD
Operating cash flow
-371,808,000 USD